A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro

Journal of Pharmaceutical Sciences

Volumn 91, Issue 9, 2002, Pages 1991-2002

  Hugger, Erin D ^a   Novak, Barbara L ^a   Burton, Philip S ^b   Audus, Kenneth L ^a   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b PFIZER INC   (United States)

Author keywords

Caco 2 cells; MDR1 MDCK cells; Membrane fluidity; P glycoprotein; Polyethoxylated excipients

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 14; CHOLESTEROL; CREMOPHOR; DOXORUBICIN; EXCIPIENT; GLYCOPROTEIN P; MACROGOL; MANNITOL; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; POLYSORBATE 80; SURFACTANT; TRITIUM;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL STRAIN CACO 2; DRUG FORMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL; MEMBRANE FLUIDITY; MONOLAYER CULTURE; NONHUMAN;

EID: 0036771081     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10176     Document Type: Article

References (40)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Hunter J, Hirst BH. 1997. Intestinal secretion of drugs: the role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 25:129-157.
3. Artursson P, Palm K, Luthman K. 1996. Caco-2 cell monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 22:67-84.
4. Hidalgo IJ, Raub TJ, Borchardt RT. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749.
5. Hilgers AR, Conradi RA, Burton PS. 1990. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 7:902-910.
6. Hunter J, Hirst BH, Simmons NL. 1993. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10:743-749.
7. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, Langguth P. 1998. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: The influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci 87:757-762.
8. Walle UK, Galijatovic A, Walle T. 1999. Transport of the flavenoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol 58:431-438.
9. Cho MJ, Thompson DP, Cramer CT, Vidmar TJ, Scieszka JF. 1989. The Madin Darby Canine Kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm Res 6:71-77.
10. Lavelle JP, Negrete HO, Poland PA, Kinlough CL, Meyers SD, Hughey RP, Zeidel ML. 1997. Low permeabilities of MDCK cell monolayers: a model barrier epithelium. Am J Physiol 42:F67-F75.
11. Braun A, Hämmerle S, Suda K, Rothen-Rutishauser B, Günthert M, Krämer SD, Wunderli-Allenspach H. 2000. Cell cultures as tools in biopharmacy. Eur J Pharm Sci 11(Suppl. 2):S51-S60.
12. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. 1988. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85:4486-4490.
13. Horio M, Chin KV, Currier SJ, Goldenberg S, Williams C, Pastan I, Gottesmann MM, Handlers J. 1989. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem 264:14880-14884.
14. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88:28-33.
15. Hugger ED, Audus KL, Borchardt RT. 2001. Effects of poly (ethylene) glycol on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci 91:1980-1990.
16. Nerurkar MM, Burton PS, Borchardt RT. 1996. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 13:528-534.
17. Nerurkar MM NFH, Ho PS, Burton TJ, Vidmar RT. 1997. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci 86:813-821.
18. Gao J, Hugger ED, Beck-Westermeyer MS, Borchardt RT. 2000. Estimating intestinal mucosal permeation of drugs using Caco-2 cell monolayers. In: Enna SJ, Williams M, Ferkany JW, Kenakin T, Porsolt RE, Sullivan JP, editors. Current protocols in pharmacology. New York: John Wiley & Sons, Unit 7.2. pp 1-23.
19. Parnaud G, Corpet DE, Gamet-Payrastre L. 2001. Cytostatic effect of polyethylene glycol on human colonic adenocarcinoma cells. Int J Cancer 92:63-69.
20. Walle UK, Walle T. 1998. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos 26:343-346.
21. Flynn GL, Yalkowsky SH, Roseman TJ. 1974. Mass transport phenomena and models: theoretical concepts. J Pharm Sci 63:479-510.
22. Ho NFH, Burton PS, Conradi RA, Barsuhn CL. 1995. A biophysical model of passive and polarized active transport processes in Caco-2 cells: Approaches to uncoupling apical and basolateral membrane events in the intact cell. J Pharm Sci 84:21-27.
23. Audus KL, Guillot FL, Braughler JM. 1991. Evidence for 21-aminosteroid association with the hydrophobic domains of brain microvessel endothelial cells. Free Radic Biol Med 11:361-371.
24. nd edition. London: The Pharmaceutical Press. pp 355-361.
25. nd edition. London: The Pharmaceutical Press. pp 375-378.
26. nd edition. London: The Pharmaceutical Press. pp 371-374.
27. Bryan AJ, Kaur R, Robinson G, Thomas NW, Wilson CG. 1980. Histological and physiological studies on the intestine of the rat exposed to solutions of Mryj 52 and PEG 2000. Int J Pharm 7:145-156.
28. Donegan L, Hudye SA, Hardin JA, Gall DG. 1990. Effect of a dietary nonionic surfactant on small intestinal nutrient transport. Digest Dis 7:902-910.
29. Oberle RL, Moore TJ, Krummel DAP. 1995. Evaluation of mucosal damage of surfactants in rat jejunum and colon. J Pharmacol Toxicol Meth 33:75-81.
30. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I. 1990. Reversal of multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50:4199-4203.
31. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH. 1992. Reversal of multidrug resistance by surfactants. Br J Cancer 66:62-68.
32. Zordan-Nudo T, Ling V, Liu Z, Georges E. 1993. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res 53:5994-6000.
33. Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS. 1995. Reversal of multidrug resistance related phenotype by surfactants: relationship to membrane fluidity. Arch Biochem Biophys 319:309-315.
34. Helenius A, Simons K. 1975. Solubilization of membranes by detergents. Biochim Biophys Acta 415(1):29-79.
35. Ferté J. 2000. Analysis of tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 267:277-294.
36. Doige CA, Yu X, Sharom FJ. 1993. The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim Biophys Acta 1146:65-72.
37. Dintaman JM, Silverman JA. 1999. Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16:1550-1556.
38. Komarov PG, Shtil AA, Buckingham LE, Balasubramanian M, Piraner O, Emanuele RM, Ronison IB, Coon JS. 1996. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function. Int J Cancer 68:245-250.
39. Badary OA, Al-Shabanah OA, Al-Gharably NM, Elmazar MMA. 1998. Effect of cremophor EL and the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice. Anti-Cancer Drugs 9:809-815.
40. Watanabe T, Nakayama Y, Naito M, Oh-hara T, Itoh Y, Tsuruo T. 1996. Cremophor EL reverse mutidrug resistance in vitro but not in tumor-bearing mouse models. Anti-Cancer Drugs 7:825-832.